Real-life study of guselkumab dosing intervals
Treatments studied
Part of Skin clinical trials.
This trial is for people with skin psoriasis who are already taking guselkumab (Tremfya) and have their shots spaced 9 weeks or longer apart. Researchers will see how well the skin is controlled with this longer interval.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult taking guselkumab (brand name Tremfya) for skin psoriasis.
- Your guselkumab shots are spaced 9 weeks or more apart.
- This trial is not for you if you take guselkumab mainly for joint pain (psoriatic arthritis).
- Your dose interval was not extended because of surgery, pregnancy, or an infection.
- Your doctor has checked your skin using a standard score (called PASI or IGA) at your visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a higher dose of guselkumab (a biologic medicine) given less frequently works as well as the standard dose for treating moderate-to-severe plaque psoriasis. The goal is to find a dosing schedule that is both effective and convenient for patients.
This study is testing a medicine called guselkumab (Tremfya) for people with psoriasis who are already taking another biologic medicine, ustekinumab, but need to switch. The goal is to see how well guselkumab works in real-world use.
This trial studies how guselkumab works for people with long-lasting, more severe psoriasis and signs that may affect joints. It may help by improving psoriasis symptoms and possibly reducing related inflammation, while researchers track safety and outcomes.
This study tracks how well patients stick with guselkumab, a biologic injection medication for moderate-to-severe plaque psoriasis. Researchers want to understand real-world treatment outcomes in Romania to help improve psoriasis care.
This study measures how much Tremfya (guselkumab) gets into breast milk for women who are already taking it for conditions like psoriasis or arthritis and choose to breastfeed. It helps understand if the drug passes to the baby.
This study follows people with psoriatic arthritis (joint pain and swelling linked to psoriasis) who are starting a newer medication called guselkumab. Researchers want to learn how long patients continue taking this medicine and how well it works for them.
Hear when a new Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.